摘要号:2014 英文标题:A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and...
高危AML患者造血干细胞移植后接受基于西达本胺的预防性治疗:中国单中心真实世界经验 Poster #2890 Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience...
188Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation 梁金花，江苏省人民医院 189Diagnostic and Prognostic Value of Circulating Cell-Free DNA in Cerebrospinal Fluid and Plasma in Newly Diagnosed D...
ASH临床实践指南：肝素诱导血小板减少症（HIT）的诊断和治疗说明书 Diagnosis and Management of Heparin-Induced Thrombocytopenia (HIT)A POCKET GUIDE FOR THE CLINICIAN DECEMBER 2018 ASH CLINICAL PRACTICE GUIDELINES VENOUS THROMBOEMBOLISM (VTE)Allyson M. Pishko, MD, University of Pennsylvania Lori-Ann Linkins...
Treatment options for patients with CLL include the following4: Watchful waiting. Radiation therapy. Chemotherapy. Immunotherapy. Targeted therapy. Clinical trials. Patients undergoing CLL treatment often experience a complete or partial response to initial therapy — but not always. Consequently, CLL can...
Impact of Diabetes on CML Treatment Another condition that can affect CML is diabetes. Results of a real-world study presented at ASH found that diabetes can affect both the clinical presentation of CML and the frontline treatment choice of patients with a new diagnosis.2 ...
Clinical trials. Patients undergoing CLL treatment often experience a complete or partial response to initial therapy — but not always. Consequently, CLL can be classified as relapsed or refractory (R/R), depending on how the disease responds to treatment. Relapsed CLL describes CLL that responded...
Highlights of the KT-333ClinicalAbstract KT-333 的亮點臨床摘要 The abstract reported Phase 1 data from 21 patients enrolled through dose level (DL) 5; 12 were evaluable for disease assessment, including 1 withcutaneous T-cell lymphoma(CTCL) and 1 withperipheral T-cell lymphoma(PTCL) at DL2,...
Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with malignant or nonmalignant hematologic disorders Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders Appraise how new...
This change has facilitated the timely initiation of treatment for patients withatypical clinical features who otherwise would not be recognized as having TTP. Conversely, excluding severeADAMTS13 deficiency focuses attention on the diagnosis and treatment of other causes of thrombotic microangiopa-thy ...